Investigation for efficacy and safety of tau PET ligand [18F]AM-PBB3
- Conditions
- Alzheimer's disease and mild cognitive impairment
- Registration Number
- JPRN-UMIN000020065
- Lead Sponsor
- ational Institute of Radiological Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 20
Not provided
1. Subjects who show obviously abnormal blood data at 1st day of the study 2. Subjects with organic brain complications/disorders (including a history of traumatic brain injury, symptomatic cerebral infarction, Parkinson's disease and similar conditions) 3. Patients with substance-related disorders (including drug abuse) 4. Subjects with severe physical complications/disorders or a history of such conditions and who are considered to be inappropriate for participation by the aforementioned doctors with responsibilities in this study 5. Subjects with a pacemaker or other metallic medical device in the body (brain clip, bolts, etc.) 6. Subjects with tattoos 7. Subjects with claustrophobia 8. Pregnant, possibly pregnant or lactating women 9. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 12 months prior to the start of this study 10. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacokinetic and quantitative analysis of [18F]AM-PBB3 Effective dose of [18F]AM-PBB3
- Secondary Outcome Measures
Name Time Method